6ix — Find Your Next Investment

Discover investor relations events, company profiles, and opportunities on 6ix. Connect with public companies and attend live investor events.

Please enable JavaScript to use all features of 6ix.com.

Originaltext

Diese Übersetzung bewerten

Mit deinem Feedback können wir Google Übersetzer weiter verbessern

Latest Press Releases

Time	Headline
2m ago	Sharon AI Appoints Mr. Andrew Penn as Chairman of the Board of Directors
2m ago	Bausch + Lomb to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
3m ago	Rigetti Signs Letter of Intent with U.S. Government for Quantum Computing Research
3m ago	Euroseas Ltd. Reports Results for the Quarter Ended March 31, 2026 and Declares Quarterly Common Stock Dividend
3m ago	Guardian Exploration Appoints Scott C. Pimm to Advisory Board to Strengthen Northern Infrastructure and Project Development Expertise

About

50.20USD+0.39 +0.78%

Closed • Updated at 11:50 GMT+00:00

Market Cap$9.70B

P/E Ratio36.63

Volume2.19M

Beta0.55

RSI34.89

Gross Margin76.28%

Health TechnologyBiotechnology

Biomarin Pharmaceutical Inc. — investor relations, events, news, and company updates on 6ix.

Latest News

BioMarin Announces Positive Phase 3 Pivotal Study Results for VOXZOGO® (vosoritide) in Children with Hypochondroplasia

BioMarin Provides Update on Phase 3 Trial for BMN 401 in Children Aged 1-12 With ENPP1 Deficiency

BioMarin Reports First Quarter 2026 Financial and Operating Results

BioMarin Presents New Data on the Effect of Long-Term Treatment with VOXZOGO® (vosoritide) on Arm Span, Bone Health and Growth in Children With Achondroplasia at the Pediatric Endocrine Society's 2026 Annual Meeting

BioMarin Completes Acquisition of Amicus Therapeutics

Community Chat

Ask AI